¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ : 2022-04-29

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ : 2022-04-29
±³À°ÀÏÀÚ : 2022-04-29
±³À°Àå¼Ò : ¿Â¶óÀΠ 
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ
´ã´çÀÚ : ¹Ú¼Ò¹Î
¿¬¶ôó : 02-398-5055  
À̸ÞÀÏ : office@kscpt.org      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¸¶ÃëÅëÁõÀÇÇаú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú¿¹¹æÀÇÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã 
±³À°½Ã°£ : 4 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í ¿Â¶óÀÎ Âü¼® : Á¤È¸¿ø 5¸¸¿ø, ÁØȸ¿ø 2¸¸¿ø / ºñȸ¿ø ÀÏ¹Ý 10¸¸¿ø, ºñȸ¿ø Çлý 5¸¸¿ø  ÇöÀåÂü¼® : Á¤È¸¿ø 7¸¸¿ø, ÁØȸ¿ø 4¸¸¿ø / ºñȸ¿ø ÀÏ¹Ý 12¸¸¿ø, ºñȸ¿ø Çлý 8¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ13:00~13:40 Special lecture : Facts and Misconceptions about Aducanumab Approval  Yaning Wang(Createrna Science and Technology) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ13:40~14:10 Model guided dose escalation in oncology Phase 1 trial  ±èÀ翬(Novartis Institutes for Biomedical Research (Cambridge MA USA)) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ14:10~14:40 Exposure-response relationship for current and future drug development  ¿ÀÀ缺(¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ14:40~15:10 Recent advances in exposure-response relationship in drug development  ±èÁ¾·ü(ÀÎÁ¦´ë ºÎ»ê¹éº´¿ø) 
Åä·Ð 04-29 ¿Â¶óÀΠ15:10~15:30 Åä·Ð  () 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ15:30~16:00 Exposure-Response in Cancer: Starting from Genomics  ±è±ÔÇ¥(¿ï»ê´ëÇб³) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ16:00~16:30 Experiences to Characterize Exposure-Response Relationship for Various Therapeutics using Modeling and Simulation: Advantages and Challenges  ÇѼºÇÊ(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ16:30~17:00 Exposure-Response RelationshipÀ» ÀÌ¿ëÇÑ ½Å¾à°³¹ß °æÇè  ÀÌÁöÀº(LG »ý¸í°úÇÐ) 
Åä·Ð 04-29 ¿Â¶óÀΠ17:00~17:20 Åä·Ð  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ : 2022-04-29""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ½ÉÀå´ë»çÁõÈıºÇÐȸ 2022 5th APCMS (Asia-Pacific CardioMetabolic Syndrome) CONGRESS(1ÀÏÂ÷) : 2022-04-29
´ÙÀ½±Û (¿Â¶óÀÎ) ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­¿ï µ¿ºÎÁöȸ ¿ù·ÊÁý´ãȸ : 2022-04-28
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20559 °æ±â Á¦34Â÷ Áß¾Ó´ëÇб³ ºñ´¢ÀÇÇаú ¿öÅ©¼¥ : 2024-06-01 0 49 2024-04-29
20558 ±¤ÁÖ Á¦2ȸ ´ëÇѺñ¸¸ÇÐȸ È£³²Áöȸ Çмú´ëȸ : 2024-06-01 0 52 2024-04-29
20557 ÀÎõ 2024³â ±èÆ÷½ÃÀÇ»çȸ Ãá°èÇмú´ëȸ : 2024-06-01 0 35 2024-04-29
20556 ¼­¿ï 2024 ´ëÇÑ¿ì¿ïÇൿ½Å°æÇבּ¸È¸ Ãá°èÇмú´ëȸ : 2024-06-01 0 39 2024-04-29
20555 ¼­¿ï ´ëÇѽÉÀåÇ÷°üÈäºÎ¿Ü°úÇÐȸ Á¦38Â÷ Ãá°èÅëÇÕÇмú´ëȸ ¹× ¿¬¼ö±³À° (2ÀÏÂ÷) : 2024-06-01 0 27 2024-04-29
20554 ¼­¿ï Á¦ 14Â÷ ´ëÇѸð¹ßÀ̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ(1ÀÏÂ÷) : 2024-06-01 0 30 2024-04-29
20553 ¼­¿ï 2024³â ´ëÇѼҾư¨¿°ÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-31 0 44 2024-04-29
20552 Àü³² ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ È£³²Áöȸ - Á¦297Â÷ ¿ù·ÊÁý´ãȸ : 2024-05-31 0 64 2024-04-29
20551 ¼­¿ï (¿Â¶óÀÎ) 2024 Çѱ¹Á¤½ÅºÐ¼®ÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-31 0 76 2024-04-29
20550 ºÎ»ê Á¦ 169Â÷ ºÎ»êÁö¹æ³²¼º°úÇÐȸ Çмú´ëȸ : 2024-05-31 0 42 2024-04-29
20549 ¼­¿ï ´ëÇѼҾư¨¿°ÇÐȸ Á¦26ȸ ¿¬¼ö°­Á : 2024-05-30 0 34 2024-04-29
20548 °­¿ø 2024³â ¿øÁÖ½ÃÀÇ»çȸ 2Â÷ ¿¬¼ö°­ÁÂ_ÃÖ±Ù ÀÇÇÐÁö°ß : 2024-05-28 0 42 2024-04-29
20547 °æ±â Á¦4ȸ ´ëÇÑ¿Ü°úÇÐȸ ¿Ü°ú³»½Ã°æ ¿¬¼ö°­Á : 2024-05-26 0 48 2024-04-29
20546 ¼­¿ï ´ëÇѺñ´¢ÃÊÀ½ÆÄÇÐȸ Á¦17Â÷ Çмú´ëȸ : 2024-05-26 0 31 2024-04-29
20545 °æºÏ 2024³âµµ °æ»óºÏµµÀÇ»çȸ Á¾ÇÕÇмú´ëȸ(2ÀÏÂ÷) : 2024-05-26 0 57 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷